Sinopharm Hyundai (600420.SH): Dapagliflozin tablets and acarbose tablets obtained drug registration certificates

Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, the company received “Drug Registration Certificates” for dagliflozin tablets and acarbose tablets approved and issued by the State Drug Administration. This time, the company's dagliflozin tablets and acarbose tablets obtained drug registration certificates and were deemed to have passed the consistency evaluation, expanding the company's drug product range in the field of endocrinology and metabolism, which is conducive to further enhancing the company's comprehensive market competitiveness in related pharmaceutical fields.

According to reports, dapagliflozin tablets are suitable for adults with type 2 diabetes (improving blood sugar with a single drug or combination treatment based on exercise or diet); extended indications include (1) adult patients with heart failure (hFREF) with reduced ejection fraction: reducing the risk of cardiovascular death and hospitalization due to heart failure; (2) adult patients with chronic kidney disease (CKD): reducing the risk of worsening renal function, end-stage renal disease, and cardiovascular death; (3) diabetic nephropathy (DKD) adults: delaying the progression of nephropathy and reducing the risk of cardiovascular death. As a hypoglycemic agent, acarbose tablets are mainly used in combination with diet control for people with type 2 diabetes and low glucose tolerance.